CO2022008784A2 - Proteínas gpcr de opsinas quiméricas - Google Patents

Proteínas gpcr de opsinas quiméricas

Info

Publication number
CO2022008784A2
CO2022008784A2 CONC2022/0008784A CO2022008784A CO2022008784A2 CO 2022008784 A2 CO2022008784 A2 CO 2022008784A2 CO 2022008784 A CO2022008784 A CO 2022008784A CO 2022008784 A2 CO2022008784 A2 CO 2022008784A2
Authority
CO
Colombia
Prior art keywords
gpcr
opsin
chimeric
protein
chimeric opsin
Prior art date
Application number
CONC2022/0008784A
Other languages
English (en)
Inventor
Sonja Kleinlogel
Wyk Michiel Van
Original Assignee
Univ Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bern filed Critical Univ Bern
Publication of CO2022008784A2 publication Critical patent/CO2022008784A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporciona una proteína GPCR de opsina quimérica que comprende una porción de opsina cadena arriba fotosensible y una porción de GPCR diana que comprende un CT quimérico que se expresa fuertemente y se dirige al compartimento subcelular correcto de las células diana. La proteína GPCR de opsina quimérica activa de forma eficaz la proteína G nativa específica de la vía de GPCR diana induciendo una respuesta fisiológica comparable a la del GPCR diana nativo. También se proporcionan moléculas de ácido nucleico que codifican la proteína GPCR de opsina quimérica así como cápsides, vectores, células y vehículos que comprenden o expresan la proteína GPCR de opsina quimérica. Asimismo, se proporciona un método de manipulación por ingeniería genética de una proteína GPCR de opsina quimérica y aplicaciones médicas de la proteína GPCR de opsina quimérica.
CONC2022/0008784A 2019-11-29 2022-06-24 Proteínas gpcr de opsinas quiméricas CO2022008784A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH15092019 2019-11-29
PCT/EP2020/083960 WO2021105509A1 (en) 2019-11-29 2020-11-30 Chimeric opsin gpcr proteins

Publications (1)

Publication Number Publication Date
CO2022008784A2 true CO2022008784A2 (es) 2022-09-20

Family

ID=73726778

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008784A CO2022008784A2 (es) 2019-11-29 2022-06-24 Proteínas gpcr de opsinas quiméricas

Country Status (17)

Country Link
US (1) US20240174743A1 (es)
EP (1) EP4065153A1 (es)
JP (1) JP2023504136A (es)
KR (1) KR20220111294A (es)
CN (1) CN115038458A (es)
AU (2) AU2020392702B2 (es)
BR (1) BR112022010095A2 (es)
CA (1) CA3162568A1 (es)
CL (1) CL2022001376A1 (es)
CO (1) CO2022008784A2 (es)
CR (1) CR20220283A (es)
EC (1) ECSP22050231A (es)
IL (1) IL293076A (es)
JO (1) JOP20220128A1 (es)
MX (1) MX2022006496A (es)
PE (1) PE20230093A1 (es)
WO (1) WO2021105509A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022420130A1 (en) * 2021-12-20 2024-07-25 Genans Biotechnology Co., Ltd ULTRA LIGHT-SENSITIVE NEUROPSIN-BASED OPTOGENETIC TOOL FOR ACTIVATING G q-COUPLED SIGNALING AND/OR ACTIVATING CELLS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022007044B1 (pt) * 2011-06-24 2023-11-14 Novartis Ag Composições farmacêuticas que compreendem uma proteína de gpcr quimérica, proteína de gpcr quimérica, molécula de ácido nucleico, e vetor

Also Published As

Publication number Publication date
JOP20220128A1 (ar) 2023-01-30
PE20230093A1 (es) 2023-01-16
ECSP22050231A (es) 2022-08-31
EP4065153A1 (en) 2022-10-05
MX2022006496A (es) 2022-09-07
CL2022001376A1 (es) 2023-03-24
BR112022010095A2 (pt) 2022-09-06
IL293076A (en) 2022-07-01
JP2023504136A (ja) 2023-02-01
AU2023241362A1 (en) 2023-10-26
CR20220283A (es) 2022-09-30
US20240174743A1 (en) 2024-05-30
CA3162568A1 (en) 2021-06-03
AU2020392702B2 (en) 2023-07-06
WO2021105509A1 (en) 2021-06-03
KR20220111294A (ko) 2022-08-09
AU2020392702A1 (en) 2022-07-21
AU2020392702A9 (en) 2022-12-08
CN115038458A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
PE20190401A1 (es) Novedosas proteinas de la capside del virus adenoasociado
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
CL2018001414A1 (es) Anticuerpos contra cd73 y sus usos (divisional solicitud 201701296)
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
MX2018011384A (es) Arn de replicacion en trans.
BR112019007281A2 (pt) proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
MX2022015081A (es) Variantes de hsd17b13 y usos de las mismas.
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
BR112017009177A2 (pt) vacinas terapêuticas contra hpv16
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
BR112012015005A2 (pt) Proteínas cry inseticidas cry1ca modificadas
BR112015021753A2 (pt) promotores de levedura provenientes de pichia pastoris
CO2022008784A2 (es) Proteínas gpcr de opsinas quiméricas
AR092152A1 (es) Uso de una region no traducida de maiz para expresion transgenica en plantas
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
NZ752941A (en) Frataxin expression constructs
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
CL2019003074A1 (es) Variantes de la proteína bmp7 humana.
EA201591723A1 (ru) Применение термофильных нуклеаз для разрушения нуклеиновых кислот
BR112023002578A2 (pt) Variantes de fitase e polinucleotídeos codificando as mesmas
CU20170036A7 (es) Mezclas que comprenden una pluralidad de polipéptidos con actividad degradante de biomasa y métodos para producir las mismas
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение